and Herceptin, a cancer drug (tier 2). The out-of-pocket cost to patients was as high as $60 for a 30-day supply purchased at preferred pharmacies with a copayment. We also found that the most common cost-sharing method for these drugs was coinsurance (with a rate most commonly 25%). Coinsurance requires Medicare beneficiaries to pay a percentage of the drug cost, which creates a greater financial burden than does a flat fee copayment. For example, patients on Aranesp ($1,098 per month) would face a monthly out-ofpocket cost of $275.
Patterns of copayment and utilization management are summarized in Table 2 . Excepting diabetes drugs, the reviewed biologics all required prior authorization. Drugs with greater coverage and within a higher cost-sharing tier (such as rheumatoid arthritis and anemia drugs) were more likely to be associated with prior authorization requirements than those within a lower cost-sharing tier (such as diabetes and cancer drugs). Other utilization management strategies were used less often. Fewer than onethird of drug plans imposed quantity limits for these biologics, and fewer than 10% of these plans used step therapy, which would require patients to try a first-line medication (generally the most cost-effective and safest drugs) before receiving coverage for a second-line medication (more costly or risky drugs). One interesting comparison of utilization management between biologics and small molecule drugs is provided by a recent study 9 that investigated coverage of small molecule drugs, such as psychotropic drugs, in Medicare Part D. Their study concludes that only a minority of Part D plans imposed prior authorization for small molecules.
In our study, coverage was found to vary both across and within drug classes (defined as therapeutic class or indication). Most plans covered at least one biologic in each drug class, ranging from 100% for diabetes drugs to 55.6% for cancer drugs. 7 or other particular circumstances 8 . This may result in a lower coverage rate under Part D.
We found that patient cost-sharing was commonly used by these plans to manage the use of these biologics. Tiered formularies are used by health plans to encourage the use of lower-cost drugs. Most of these biologics were classified in tier 4, which requires the greatest cost-sharing, except for diabetes drugs (tiers 2 or 3)
To the Editor: 'Biologics' are therapeutics produced through recombinant DNA technology or other biological processes. The number of available biologics and expenditures for them have increased dramatically in recent years. Although insurance coverage policies must balance patient and societal needs of access and affordability, insurers may also adopt strategies to manage the use of these expensive drugs. Such strategies include a more complex tiered formulary (drugs are divided into "tiers," with the first tier typically representing generics at the lowest level of patient cost-sharing, and a higher tier requiring higher patient cost-sharing), prior authorization (requiring physicians to obtain approval from the health plan before prescription for coverage) and the use of specialty pharmacy vendors 1-3 . Despite the growing importance of biologics, little is known about their coverage, cost-sharing and management tools, or how they vary across drug characteristics. Current evidence is limited to studies of selected health plans 2,3 , geographical areas 4 or diseases 5 .
We examined coverage, cost-sharing and utilization management for the top-selling biologics in 2006 and 2009 using nationally representative data from the US Medicare prescription drug plan formulary files as in Table 1 . The unit of analysis was each Part D product (that is, at each organization and plan combination). Our research goal was to understand how common biologics were covered. We analyzed the top 20 biologics (per global sales in 2006) with three specific aims: first, baseline patterns in coverage, cost-sharing and utilization management for 2006; second, whether coverage varied by drug characteristics (presence of a 'black box' warning and monthly costs); and finally, trends in insurance coverage policies between 2006 and 2009.
We analyzed Medicare Part D drug coverage for several reasons. First, this program has expanded coverage for patients and thus has had a strong impact on drug demand. Second, Medicare coverage Table 2 ). In general, we found that an increasing number of plans included these biologics in their formularies in 2009, especially for cancer drugs and Levemir (which was a new drug in 2006). However, in 2009, more plans have adopted coinsurance as the cost-sharing method of choice for these biologics (except diabetes drugs), increased the coinsurance rate (with a most common rate of 33% in 2009 versus 25% in 2006), and raised the copayment amount. Prior authorization and quantity limit also increased significantly for most of the biologics studied.
Medicare formulary coverage for top-selling biologics
In sum, top-selling biologics were covered by most Medicare prescription drug plans in 2006, but access to these biologics was limited by high patient glargine)) was present in nearly every (97.8%) plan.
We also examined whether coverage varied by drug characteristics (data not shown but available upon request). Two drug characteristics were examined: presence of a black box warning and monthly costs. A black box warning is a labeling requirement imposed by the FDA indicating that a drug may cause serious adverse effects. In general, drugs with a black box warning and higher monthly costs were associated with less coverage, a higher cost-sharing tier, and prior authorization requirements by most Medicare prescription drug plans.
Next, we investigated trends over time by comparing coverage patterns of 2006 and Within the same drug class, coverage varied. Therapeutics in some indications were covered similarly, irrespective of the drug. For example, the least-covered rheumatoid arthritis treatment was present in 91.9% of plans, whereas the most-covered was present in 99.6% of plans. Similarly, the least-covered cancer medication was present in 42.1% of plans, whereas the most-covered was in 45.9% of plans. In other indications, however, there was a much larger variation of coverage. Thus, the least-covered anemia medication was present in 65.8% of plans, whereas the most-covered was in 95.4%; the least-covered diabetes drug (Levemir) was present in only 11% of plans, whereas the most-covered drug (Lantus (insulin cost-sharing and prior authorization requirements. In 2009, patient cost-sharing and utilization management requirements have increased still further. In addition, we found significant variations by drug, drug class and drug characteristics. Our findings serve as a first step toward understanding and addressing the coverage issues for these expensive biologics, with important implications for drug access, formulary decisions and strategic planning for drug development. The results on coverage, cost-sharing and prior authorization for biologics are in general consistent with other studies examining the specialty tiers broadly [10] [11] [12] . Further research is needed to understand the impact of policies that relate formulary placement, such as codifying protected drug classes, to model patient out-of-pocket expenditures under different cost-sharing scenarios. a Among plans that use copayments, the copayment amount that was most frequently used among the Medicare prescription drug plans. b The percentage of the Medicare prescription drug plans that required prior authorization for the drug. c The percentage of the Medicare prescription drug plans that imposed a quantity limit on the drug.
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